cyrilzakka/clinical-trials huggingface dataset:
Clinical Effectiveness of S53P4 Bioactive Glass in Treatment of Long-bone Chronic Osteomyelitis

This clinical trial studies the clinical effectiveness of S53P4 bioactive glass (BAG) as a bacterial growth inhibiting bone graft substitute in a one-stage or two-stage surgical procedure for treatment of chronic long bone osteomyelitis.

In this prospective multicenter study, patients from two different university hospitals in the Netherlands were included. Treatment consisted of debridement surgery, implantation of S53P4-BAG, if necessary wound closure by a plastic surgeon and additional culture based systemic antibiotics. Primary outcome was eradication of infection based on clinical presentation, radiographic imaging and laboratory tests. Secondary analysis was performed on probable risk factors for treatment failure after S53P4-BAG implantation.

Eligibility Criteria:
Inclusion Criteria:

* Patients with a clinical, radiographic and/or laboratory study confirmed chronic osteomyelitis of long bones
* Patients who are physically and mentally willing and able to comply with postoperative functional evaluation.
* Patients that can read and understand the Dutch language.

Exclusion Criteria:

* Patients with an diabetic ulcer related chronic osteomyelitis
* Patients that are pregnant.
* Patients who are unwilling to cooperate with the study protocol and follow-up schedule.
* Patients who, as judged by the surgeon, are mentally incompetent or are likely to be non-compliant with the prescribed post-operative routine and follow-up evaluation schedule.
* Patients with malignancy - active malignancy within last 1 year
* Patients known with a diagnosed systemic disease that would affect the subject's welfare or overall outcome of the study (severe osteoporosis requiring medication, Paget's disease, renal osteodystrophy,hypercalcemia ) or is immunologically suppressed, or receiving steroids in excess of physiologic dose.
* Patients with a neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device or the patient has a neurological deficit which interferes with the patient's ability to limit weight bearing or places an extreme load on the implant during the healing period.
* Patients with systemic or metabolic disorders leading to progressive bone deterioration
* Patients with other concurrent illnesses that are likely to affect their outcome such as all autoimmune diseases (including RA), sickle cell anaemia, systemic lupus erythematosus, psoriasis, not controlled type 1/2 diabetes or renal disease requiring dialysis.
* Patients with a known sensitivity to device materials
* Patients that are an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse
Effectiveness of Resistive Capacitive Diathermy in Patients Affected by Knee Osteoarthritis

It is a double-blind randomized sham-controlled clinical trial to evaluate the effectiveness of resistive capacitive diathermy in subjects affected by knee osteoarthritis in comparison with a "sham" diathermy treatment. The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W, used to reduce pain and inflammation and allowing healing processes. The sham diathermy treatment is administered with the device set on "on" but not active (not supplying energy). Each subject, randomly assigned to either resistive capacitive diathermy treatment (group 1) or sham-treatment (group 2) is submitted to a thirty minutes session, three times per week for a total of ten sessions. The outcome measures are the WOMAC scale (Western Ontario and McMaster Universities Arthritis Index) to assess pain and physical functioning, a visual analogic scale (VAS) for pain, the femoral quadriceps strength (MRC = Medical Research Council Scale). Outcome measures are administered at baseline (T0), at the end of the treatment protocol (T1), at 1 month (T2) and 3 months (T3) after the end of treatment.


Eligibility Criteria:
Inclusion Criteria:

* Patients affected by Knee osteoarthritis established by clinical examination and X-ray in postero-anterior and lateral views

Exclusion Criteria:

* Neurologic Disorders involving the lower limbs
* Systemic inflammatory disorders
* pace-maker implantation
* Severe heart disease
* Acute infections or bone tuberculosis
* Acute skin diseases
* History of surgery on the affected knee
* Cognitive or psychiatric disorders
Interest of Positive Expiratory Pressure (PEP) Delivery by EzPAP® After Cardiac Surgery in the Management of Postoperative Atelectasis

Pulmonary atelectasis is a frequent respiratory postoperative complication in cardiac surgery. Classically, the treatment of these patients is based on manual chest physiotherapy. Our objective is to evaluate the interest of association of positive end expiratory delivery sessions with the EzPAP® device. We perform a prospective monocentric, open label trial. Patients with atelectasis after scheduled cardiac surgery with cardiopulmonary bypass are included. They benefit from manual chest therapy and are randomised to receive or not positive end expiratory pressure sessions twice a day. The primary endpoint is the effect of this treatment on atelectasis radiological score after 2 days of treatment. The secondary endpoints are: oxygen saturation(SpO2)/inspired oxygen(FiO2) ratio, qualitative evaluation of ventilatory function, respiratory \& cardiac rate, pain, inspiratory pressure (sniff test), patient satisfaction, duration of intensive care unit (ICU) and hospital stay.


Eligibility Criteria:
Inclusion Criteria:

* Patients admitted in ICU after cardiac surgery by sternotomy with cardiopulmonary bypass presenting a pulmonary atelectasis after extubation, diagnosed by chest X-ray in postoperative period (day1 to day 2).
* Patients over 18 years of age
* Informed patient

Exclusion Criteria:

* Cardiac arrhythmia
* Hemodynamic instability (mean blood pressure \< 65 mmHg or \> 95 mmHg)
* Respiratory rate \> 35/min
* Undrained pneumothorax
* Predictable trachea intubation or emergent surgery
* Patient oral refusal
Follow-up Studies of Primary Snoring(PS) and Obstructive Sleep Apnea Hypopnea Syndrome(OSAHS) in Chinese Children

The study is designed to investigate the natural course of Primary snoring in 1-2 years or more and the different effect of drug and surgical treatment applied in children with obstructive sleep apnea (OSAS) by comparing the polysomnography(PSG) and sleep questionaires in 6 months after treatment.

The evolution of snoring and OSAS in children is not well established since few studies have been published.This study is designed to evaluate the evolution of primary snoring and OSAS in children who had been submitted to watchful waiting 、drug or adenotonsillectomy.The participated children will be evaluated by full physical examination and nocturnal polysomnography（PSG）, after which they were divided into 2 groups: apnea and snoring. After 6 months following the initial evaluation, patients were submitted to a new nocturnal polysomnography, and all data were compared to those of the first examination.And after 3 months and 12 months following the initial evaluation, patients will be called to complete the sleep questionnaire.Then analyse the change of parameters of polysomnography after 6 months of follow-up,and describe the changes of items of sleep questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Children aged 3-12 yrs, who are referred for clinical evaluation of habitual snoring and who were scheduled for an overnight polysomnogram.

Exclusion Criteria:

* Children who are suffered from any chronic medical or psychiatric condition
* Children with acute respiratory infection
* Children with severe craniofacial deformities
* Children with cardiopulmonary diseases
* Children with a genetic syndrome that was known to affect cognitive abilities, or are receiving medications that are known to interfere with memory or sleep onset or heat rate
What do Parents Know About Space Maintainers

Space maintainers are frequently used to prevent malocclusion problems in early primary tooth loss. Oral health literacy is defined as the capacity of individuals to learn, understand and evaluate basic oral health information. It is considered that parents' awareness of space maintainers may be affected by various factors such as their demographic characteristics and oral health literacy. The aim was to evaluate the relationship between variables by determining parents' awareness of space maintainers and their oral health literacy.

This cross-sectional study included 600 children and their parents. The survey, which included questions about sociodemographic characteristics and space maintainer awareness, was administered to parents face to face. Then, parents' oral health literacy levels were measured with TREALD-30 and TREALD-30A scales.

Eligibility Criteria:
Inclusion Criteria:

* Patients who did not require urgent treatment,
* Who did not use medication for psychiatric reasons,
* Who did not have any mental illness were included.

Exclusion Criteria:

* Those who did not meet the inclusion criteria were excluded from the study.
Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis

The purpose of this study is to help understand if by adding Niaspan FCT (study drug) to antipsychotic medications will it help maintain or improve cognitve functioning.


Eligibility Criteria:
Inclusion Criteria:

ALL SUBJECTS

1. Must understand the nature of the study, must provide written informed consent prior to the conduct of any study procedures/assessments and are willing/able to participate in study procedures/assessments as specified in this protocol.
2. Must be between the ages of 18 - 35

PATIENTS

1. Within one year of initial DSM 1V TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS
2. Outpatients
3. Females of child bearing potential who have a negative serum pregnancy test prior to enrolment and agree to use a reliable method of birth control (use of oral contraceptives or Norplant; contraceptive injections; contraceptive patch; double barrier method; intrauterine devices; partner with vasectomy or abstinence) during the study and for one month following the last dose of study drug.

HEALTHY CONTROLS

1. Age-matched to experimental groups

Exclusion Criteria:

1. Due to their underlying mental disorder are considered by the investigator(s) to be unable to provide informed consent and/or unwilling or unable to participate in study procedures/assessments
2. Are judged by the investigator(s) (based on history, mental status examination or clinical impression) as being at significant risk of self-injurious/suicidal or violent/homicidal behaviour
3. Meet criteria for substance abuse or dependence (excluding nicotine and caffeine) as defined by DSM IV-TR at the time of screening and/or within the preceding 6 months
4. Have unstable medical, psychiatric, neurological or behavioural disorders that may interfere in the conduct or interpretation of the study.
5. Have a history of pre-existing liver dysfunction and/or at screening have abnormal liver function tests (ALT\>2x upper limit of normal; AST\>3x upper limit of normal; Bilirubin\>1.5x upper limit of normal)
6. Have a past or current history of peptic ulcer, gout or bleeding problems
7. Have a past or current history of hypophosphatemia
8. Have a history of head injury resulting in loss of consciousness of \> 5 minutes or other neurological disorder (e.g., seizures, stroke, MS)
9. Are currently taking a vitamin or nutritional supplement containing a dose of niacin/nicotinic acid above 100 mg/day.
10. Are currently receiving treatment with any of the following medications:

    1. Anticoagulants
    2. Statins
    3. Antihypertensives
11. Are currently receiving treatment for Type 1 or Type 2 diabetes
12. Have a history of allergic reactions to NIASPAN or any of its non-medicinal ingredients (methylcellulose, povidone, stearic acid), niacin or nicotinic acid
13. Are currently participating in any other investigational drug study
14. Are a professional or staff member affiliated with the Nova Scotia Early Psychosis Program or are an immediate family member defined as spouse, parent, child, sibling, grandparent or grandchild
Quantitative Assessment of Signal Loss in Cardiotocography Using External Recording

Signal loss in cardiotocography (CTG) recordings is numerous and frequent, whether due to artifacts in signal acquisition or confusion over inadvertent maternal heart rate recording, with various negative consequences for neonatal morbidity and unnecessary obstetric interventions. Data on this issue are 10 to 15 years old. CTG remains the primary method for assessing fetal well-being during labor, almost systematically.


Eligibility Criteria:
Inclusion Criteria:

* Adult female (≥ 18 years old)
* Patient treated at a hospital between February 1, 2024 and February 28, 2024
* Having undergone cardiotocography in the labor and delivery room
* Gestational age at delivery \>36 weeks

Exclusion Criteria:

* Patient who has expressed opposition to the use of medical record data
* Patient without CTG
* Gestational age at delivery \<36 weeks
CBCR for Executive Functions in Patients With ABI in the Chronic Phase

This study examines the effects of computerbased cognitive rehabilitation on executive functions in the chronic phase after acquired brain injury

This study examines the effects of computerbased cognitive rehabilitation on executive functions in the chronic phase after acquired brain injury using two clinically developed programmes and one sham-intervention. Furthermore, the study consists of Groups that receives the computerized training both with and witouth support from a professional.

Eligibility Criteria:
Inclusion Criteria:

* Persons who are able to give an informed consent both verbally and in writing
* Persons in the chronic phase after stroke or traumatic brain injury (more than one year post onset)
* Persons who score less than the 30. Percentile in one or more of the primary outcome measures outlined above.

Exclusion Criteria:

* Persons with neurodegenerative diseases
* Persons with diseases which can influence executive functions such as ADHD
* Persons who are motorically or cognitively unable to use a tablet and complete the CBCR-training
Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hospital in the UK: an Ecological Study

The impact of rotavirus vaccination on the burden of disease has been well documented. However, the anticipated reduction in hospital pressures has yet to be described. This study will provide quantitative measures of hospital pressure prior to and post vaccine introduction, provide a template for future hospital pressures studies related to vaccine introduction and provide measures which could be used in an economic evaluation.


Eligibility Criteria:
Inclusion Criteria:

* All children aged ≤15 years being hospitalised (with overnight stay or day clinic) for whatever reason during the study period

Exclusion Criteria:

* None
Warfarin and Coronary Calcification Project

The purpose of the study is to assess whether the use of warfarin, a commonly used anticoagulation drug, is associated with increased amounts of coronary artery calcification. Studies in animals and preliminary but small retrospective studies in humans have suggested a possible link to increased tissue calcification with use of this drug. The researchers will investigate this by assessing the amount of calcification seen in the coronary arteries using a specialized computed tomography (CT) scan (electron-beam CT) and assessing to see if the amount is influenced by the amount of time a patient has been taking warfarin. The researchers will exclude patients with known coronary artery disease, chronic kidney disease or hyperparathyroidism.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years of age or older
* Patients referred to begin or already treated with warfarin anticoagulation therapy.

Exclusion Criteria:

* Known prior myocardial infarction or coronary heart disease
* History of advanced chronic kidney disease manifested by serum creatinine\>2 or calculated glomerular filtration rate (GFR)\<30
* History of hyperparathyroidism
* Current hypercalcemia
* Current hyperphosphatemia
* Uncertain duration of warfarin therapy
* Lack of records documenting international normalized ratio (INR) during therapy
Hashimoto's Thyroiditis in Upper Egypt

The aim of this study is to evaluate the pathological pattern, characteristic features, treatment, complications and prognosis of Hashimoto's thyroiditis in upper Egypt.


Eligibility Criteria:
Inclusion Criteria:

* All patients with Hashimoto's thyroiditis, males or females, any age, at upper egypt .

Exclusion Criteria:

* Patients with associated other thyroid pathology other than Hashimoto's thyroiditis.
Determinants of Cardiac Risk Factor Modification in Latinos With Coronary Artery Disease

This is an observational study among Latino patients who have coronary artery disease. The goal of the study is to determine the association between having depressive symptoms and the ability to modify one's health behavior. Specifically, participate in physical activity.

Specific aims: Among 213 Latino adult patients who have had coronary artery angioplasty within the past month, the specific aims of the proposed study are:

1. To determine whether patients who have more depressive symptoms at the time of angioplasty are less likely to be active in physical activity at two years. Physical activity will be measured by a survey that asks patients to describe their activities including leisure activities or housework.
2. To determine whether lower perceived social support, lower self-efficacy for engaging in physical activity, and greater perceived stress mediate the effects of depressive symptoms on participation in physical activity.

Long-term objectives: The long-term objective of this study is to use these data to develop a culturally tailored intervention to increase participation in physical activity and ultimately improve the overall health and well being of Latino adults with coronary artery disease.

Outcome: The outcome is being in the action or maintenance stage of physical activity two years after angioplasty The stage of physical activity participation will be based on the Stages of Change model. This model describes behavior change as a continuum from pre-contemplation to contemplation.

Eligibility Criteria:
Inclusion Criteria

* Patients must identify their ethnicity as Latino or Hispanic
* Patients must be able to complete a questionnaire in either English or Spanish.
* Patients must have angiographic evidence of coronary artery disease requiring angioplasty
* Patients must also be clinically stable for an interview
* Patient must be able to provide informed consent.

Exclusion criteria

* Patients who are not clinically stable such as those who had cardiac arrest, who are intubated, who have active psychosis, or who are cognitively impaired.
* Patients who are unable to provide consent.
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.


Eligibility Criteria:
* Diagnosis of cancer, excluding primary or metastatic brain tumors.
* Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry.
* Physical/neurological examination consistent with the absence of a focal neurological deficit
* Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).
* Subjects must be able to adhere to the protocol requirements.
* Subjects must understand and voluntarily sign an informed consent document.
* Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.
Photobiomodulation in Post Menopause Genitourinary Syndrome

The goal of this project is to evaluate the clinical response of patients with symptoms of genitourinary menopause syndrome after the application of photobiomodulation in the vagina and its introit. METHOD: In this randomized, double-blind, placebo-controlled study protocol, women over 50 years of age who are in the postmenopausal period (amenorrhea for at least 12 months, with no pathology involved) with one or more symptoms of PGS will be selected. Participants included in the study will be randomly divided into two groups: group A, which will receive photobiomodulation with a vaginal diode laser and its introit and group B (placebo) with the laser device turned off. Both treatments will be maintained for 4 consecutive weeks.The treatment group (n=30) will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for the 40s in each site, once per week for 4 weeks. The Placebo Group (n=30) will be handled as treated, but with the laser turned off. Quality of life will be analyzed using the female sexual functioning index (FSFI-6), the urinary incontinence questionnaire (ICIQ-SF), the intensity of menopausal symptoms will be evaluated using a visual analogue scale (VAS), the vulvo vaginal atrophy will be measured by the Vaginal Health Index (VHI) and compared between groups. Also, the vaginal temperature will be measured using a thermal camera, as well as the pressure of the pelvic floor force (vaginal dynamometer) and a 1-hour Pad Test will be performed to quantify the urinary loss. The data will be tested for normality using the Shapiro Wilks test and, if they present a parametric distribution, they will be represented by means of their respective means and standard deviations.


Eligibility Criteria:
Inclusion Criteria:

* Women over 50 years of age who are in the postmenopausal period (amenorrhea for at least 12 months, with no pathology involved);
* With one or more symptoms of UGS (dyspareunia, dryness, irritation and vaginal burning and/or discomfort, vaginal atrophy, vaginal and vulvar dryness, dysuria, frequency, recurrent urinary infections);
* With complaints of stress and/or urge urinary incontinence;
* Who have cervical cytopathology (Pap smear) within the normal range performed in the last year and are not in use of hormonal medication to treat menopausal symptoms in the last 6 months.

Exclusion Criteria:

* Participants with explicit refusal of the patient to participate in the researc;
* History of bilateral oophorectomy and diseases such as: recent AMI (Acute Myocardial Infarction), neoplasms, history of thrombosis, liver failure, uncontrolled genital bleeding, genital condylomatosis, active genital herpes, lower genital tract surgeries that make treatment impossible.